Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

INTERFERON BETA for Relapsing-remitting multiple sclerosis: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 25 adverse event reports in the FDA FAERS database where INTERFERON BETA was used for Relapsing-remitting multiple sclerosis.

Most Reported Side Effects for INTERFERON BETA

Side Effect Reports % Deaths Hosp.
Off label use 95 35.7% 8 64
Eosinophilia 46 17.3% 0 45
Pruritus 30 11.3% 1 28
Rash maculo-papular 27 10.2% 0 27
Drug ineffective 26 9.8% 2 8
Multiple sclerosis relapse 26 9.8% 0 6
Rash 24 9.0% 1 22
Dizziness 23 8.7% 0 8
Pyrexia 21 7.9% 2 14
Ataxia 15 5.6% 0 0
Central nervous system lesion 15 5.6% 0 0
Gait disturbance 15 5.6% 0 5
Insomnia 15 5.6% 0 2
Anxiety 14 5.3% 0 1
Fall 14 5.3% 0 2

Other Indications for INTERFERON BETA

Covid-19 pneumonia (52) Multiple sclerosis (48) Covid-19 (43) Product used for unknown indication (33) Chronic hepatitis c (13) Pineal parenchymal neoplasm malignant (10) Hepatitis c (5)

Other Drugs Used for Relapsing-remitting multiple sclerosis

OCRELIZUMAB (15,658) FINGOLIMOD (8,814) OFATUMUMAB (3,864) DIMETHYL (3,638) NATALIZUMAB (2,749) INTERFERON BETA-1A (2,058) GLATIRAMER (1,965) ALEMTUZUMAB (1,604) TERIFLUNOMIDE (1,320) RITUXIMAB (956)

Related Pages

INTERFERON BETA Full Profile All Relapsing-remitting multiple sclerosis Drugs INTERFERON BETA Demographics INTERFERON BETA Timeline